DK3255141T3 - Fremstilling af antistoffer med forbedret glycosyleringsmønster - Google Patents

Fremstilling af antistoffer med forbedret glycosyleringsmønster Download PDF

Info

Publication number
DK3255141T3
DK3255141T3 DK17179340.9T DK17179340T DK3255141T3 DK 3255141 T3 DK3255141 T3 DK 3255141T3 DK 17179340 T DK17179340 T DK 17179340T DK 3255141 T3 DK3255141 T3 DK 3255141T3
Authority
DK
Denmark
Prior art keywords
antibodies
preparation
glycosylation pattern
improved glycosylation
improved
Prior art date
Application number
DK17179340.9T
Other languages
English (en)
Inventor
Daniel R Lasko
Stephan M Koza
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3255141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK3255141T3 publication Critical patent/DK3255141T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
DK17179340.9T 2006-07-13 2007-07-11 Fremstilling af antistoffer med forbedret glycosyleringsmønster DK3255141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13
EP12164058.5A EP2495307B9 (en) 2006-07-13 2007-07-11 Production of coagulation factor IX with improved glycosylation pattern

Publications (1)

Publication Number Publication Date
DK3255141T3 true DK3255141T3 (da) 2022-01-31

Family

ID=38645762

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17179340.9T DK3255141T3 (da) 2006-07-13 2007-07-11 Fremstilling af antistoffer med forbedret glycosyleringsmønster
DK07796784T DK2041270T3 (da) 2006-07-13 2007-07-11 Fremstilling af glycoproteiner
DK12164058.5T DK2495307T5 (da) 2006-07-13 2007-07-11 Fremstilling af koagulationsfaktor IX med forbedret glycosyleringsmønster

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07796784T DK2041270T3 (da) 2006-07-13 2007-07-11 Fremstilling af glycoproteiner
DK12164058.5T DK2495307T5 (da) 2006-07-13 2007-07-11 Fremstilling af koagulationsfaktor IX med forbedret glycosyleringsmønster

Country Status (23)

Country Link
US (1) US8129145B2 (da)
EP (3) EP2495307B9 (da)
JP (1) JP5401310B2 (da)
KR (1) KR101495549B1 (da)
CN (2) CN104878064A (da)
AR (1) AR061976A1 (da)
AU (1) AU2007272957B2 (da)
BR (1) BRPI0714212B8 (da)
CA (1) CA2657248C (da)
DK (3) DK3255141T3 (da)
ES (2) ES2440487T3 (da)
HK (1) HK1214307A1 (da)
HU (1) HUE039128T2 (da)
IL (1) IL196252A (da)
MX (1) MX2009000349A (da)
PE (1) PE20081194A1 (da)
PL (2) PL2041270T3 (da)
PT (2) PT2041270E (da)
RU (1) RU2463345C2 (da)
SI (1) SI2495307T1 (da)
TR (1) TR201807021T4 (da)
TW (1) TW200812577A (da)
WO (1) WO2008008360A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
TWI548747B (zh) 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
ES2541546T3 (es) * 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CN101679941A (zh) * 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
ES2535734T3 (es) 2008-10-20 2015-05-14 Abbvie Inc. Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
WO2011011674A2 (en) * 2009-07-24 2011-01-27 Dr. Reddy's Laboratories Ltd. Production of erythropoiesis stimulating protein using metal ions
MX344786B (es) * 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
PT2563906T (pt) 2010-04-26 2018-02-16 Novartis Ag Processo para cultivo de células cho
BR112013018751B1 (pt) * 2010-12-28 2021-01-05 Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.) método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
DK2702164T3 (da) 2011-04-29 2016-02-01 Biocon Res Ltd Fremgangsmåde til reduktion af heterogenitet af antistoffer og fremgangsmåde til fremstilling af disse antistoffer
AU2012283858C1 (en) 2011-07-20 2020-01-23 Zepteon, Incorporated Polypeptide separation methods
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
SG11201601262QA (en) * 2013-08-20 2016-03-30 Lek Pharmaceuticals CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015128795A1 (en) 2014-02-25 2015-09-03 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
DK3110961T3 (da) * 2014-02-27 2020-02-03 Hoffmann La Roche Modulering af cellevækst og glycosylering i rekombinant glycoproteinproduktion
PT3227454T (pt) 2014-12-01 2020-04-06 Amgen Inc Processo para a manipulação do nível do teor de glicano de uma glicoproteína
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3303559A1 (en) 2015-06-01 2018-04-11 Biogen MA Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
NZ781142A (en) 2019-12-06 2023-05-26 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
WO2022204120A1 (en) * 2021-03-23 2022-09-29 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) * 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
ES2335720T3 (es) 1991-01-21 2010-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
WO1998017799A1 (en) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999035255A2 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
EP1078093B1 (en) 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
EP1117435B1 (en) 1998-09-30 2007-11-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ES2281342T3 (es) 1999-04-26 2007-10-01 Genentech, Inc. Proceso de cultivo de celulas para la produccion de glicoproteinas.
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
ES2254403T3 (es) 2000-03-22 2006-06-16 Octagene Gmbh Produccion de muteinas recombinantes de factor de coagulacion sanguinea viii en lineas de celulas humanas.
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ES2916174T3 (es) 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
JP4510938B2 (ja) 2002-07-15 2010-07-28 イミュネックス・コーポレーション 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
PE20070796A1 (es) 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
AU2006312014A1 (en) 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
WO2007070315A2 (en) * 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein

Also Published As

Publication number Publication date
BRPI0714212B1 (pt) 2021-01-19
EP3255141B1 (en) 2021-12-01
KR20090029841A (ko) 2009-03-23
AU2007272957B2 (en) 2014-05-01
EP2041270A1 (en) 2009-04-01
PT2495307T (pt) 2018-05-10
EP2495307B1 (en) 2018-02-21
SI2495307T1 (en) 2018-05-31
CA2657248C (en) 2018-10-30
TW200812577A (en) 2008-03-16
TR201807021T4 (tr) 2018-06-21
AR061976A1 (es) 2008-08-10
JP2009543550A (ja) 2009-12-10
US8129145B2 (en) 2012-03-06
RU2008152449A (ru) 2010-08-20
PL2495307T3 (pl) 2018-07-31
WO2008008360A1 (en) 2008-01-17
MX2009000349A (es) 2009-03-09
BRPI0714212B8 (pt) 2021-05-25
ES2668212T9 (es) 2018-05-30
KR101495549B1 (ko) 2015-02-25
ES2440487T3 (es) 2014-01-29
EP2495307A1 (en) 2012-09-05
JP5401310B2 (ja) 2014-01-29
PT2041270E (pt) 2013-12-27
BRPI0714212A2 (pt) 2013-03-26
PE20081194A1 (es) 2008-09-22
ES2668212T3 (es) 2018-05-17
EP2041270B1 (en) 2013-11-20
HK1214307A1 (zh) 2016-07-22
CA2657248A1 (en) 2008-01-17
DK2495307T3 (da) 2018-05-07
EP3255141A1 (en) 2017-12-13
CN101541950A (zh) 2009-09-23
AU2007272957A1 (en) 2008-01-17
DK2041270T3 (da) 2014-01-27
RU2463345C2 (ru) 2012-10-10
HUE039128T2 (hu) 2018-12-28
IL196252A0 (en) 2011-08-01
EP2495307B9 (en) 2018-05-02
CN104878064A (zh) 2015-09-02
IL196252A (en) 2016-02-29
PL2041270T3 (pl) 2014-04-30
US20080081356A1 (en) 2008-04-03
DK2495307T5 (da) 2018-07-16

Similar Documents

Publication Publication Date Title
DK3255141T3 (da) Fremstilling af antistoffer med forbedret glycosyleringsmønster
DK1981859T3 (da) Fremstilling af delmopinol
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1879844T3 (da) Fremstilling af natriumdiformiat
DK2126093T3 (da) Forbedring af proteinfremstilling
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK2527713T3 (da) Blender med stigningsgrad
DK2700786T3 (da) Modifikation af overførselspassage
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2131860T3 (da) Anti-sclerostin-antistoffer
DK1877568T4 (da) Hydrolysering af arabinoxylan
DK1989008T3 (da) Fremstilling af sekundære aggregater
DE112007002915A5 (de) Verstelleinrichtung
DK2040814T3 (da) Keramisk filter
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2073636T3 (da) Fremgangsmåde til fremstilling af oxymorphon
DK1940465T3 (da) Ny anvendelse af anti-IL-1beta-antistoffer
NO20055643D0 (no) Preparation of lodixanol
DK2111555T3 (da) Diagnosticering af præeklampsi
DK1934027T3 (da) Fremstilling af modificerede lignocellulosematerialer
DK2083629T3 (da) Krystallinsk modifikation af fipronil